MedTrace Logo

Nanoparticles Analysis in Lung and Bronchi During Various Pulmonary Interstitial Diseases and Relationships With Their Aetiology

NCT02549248 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 100

Last updated 2015-09-15

No results posted yet for this study

Summary

Nanoparticles (NP) are particles whose length, width and height are less than 100 nanometres. Over the past decade, industrial applications of NP have increased dramatically. Despite their widespread use, their true impact on human health remains unknown and poorly studied. NP exposure in humans primarily occurs via inhalation through the respiratory system. The aim of this study is to estimate the relationships between the nanoparticle load in the lung and bronchi and some interstitial lung diseases. In the aftermath of human exposure to asbestos, the pathological consequences of environmental exposure to nanomaterials could be evaluated upon a mineralogical analysis of pulmonary samples.

Conditions

  • Interstitial Lung Diseases

Interventions

OTHER

BAL

Patients with idiopathic and non idiopathic interstitial lung diseases

OTHER

BW

Patients with idiopathic and non idiopathic interstitial lung diseases

OTHER

EAC

Patients with idiopathic and non idiopathic interstitial lung diseases

OTHER

blood specimen

Patients with idiopathic and non idiopathic interstitial lung diseases

OTHER

Urine specimen

Patients with idiopathic and non idiopathic interstitial lung diseases

Sponsors & Collaborators

  • Centre Hospitalier Universitaire de Saint Etienne

    lead OTHER

Principal Investigators

  • Jean-Michel VERGNON, PhD · CHU SAINT-ETIENNE

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-12-31
Primary Completion
2015-04-30
Completion
2015-04-30

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02549248 on ClinicalTrials.gov